Strs Ohio Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Strs Ohio increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,960 shares of the medical research company’s stock after buying an additional 1,363 shares during the period. Strs Ohio’s holdings in Charles River Laboratories International were worth $8,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. purchased a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $400,000. Louisiana State Employees Retirement System acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at about $733,000. WCM Investment Management LLC purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth about $1,396,000. Ingalls & Snyder LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth about $204,000. Finally, Keystone Financial Services purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $204,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

CRL has been the topic of a number of research reports. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. UBS Group lifted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Citigroup upped their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird lifted their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Evercore ISI upped their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Price Performance

Shares of CRL opened at $229.90 on Thursday. The firm has a 50-day simple moving average of $253.47 and a two-hundred day simple moving average of $220.92. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The stock has a market cap of $11.84 billion, a PE ratio of 24.96, a P/E/G ratio of 1.85 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. During the same quarter last year, the firm earned $2.98 EPS. The firm’s revenue for the quarter was down 7.9% on a year-over-year basis. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).